Loading clinical trials...
Loading clinical trials...
* Primary purpose: To assess satisfaction with overall improvement in symptoms, including individual bowel symptoms, after 4 weeks of administration of gQ-lab to patients with irritable bowel syndrome...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
IlDong Pharmaceutical Co Ltd
NCT07481422 · Irritable Bowel Syndrome (IBS)
NCT07283341 · Irritable Bowel Syndrome (IBS)
NCT04506593 · Eosinophilic Esophagitis, Gastroesophageal Reflux Disease (GERD), and more
NCT06657001 · Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), and more
NCT06583395 · Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, and more
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions